ClinicalTrials.gg
CompletedNCT06192589Updated Jul 31, 2025Results posted

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

A Phase 1 interventional study of Cannabidiol and Placebo in Cannabidiol, Drug Induced Liver Injury and Drug Interaction, sponsored by Food and Drug Administration (FDA). Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Food and Drug Administration (FDA) · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Chemical and Drug Induced Liver Injury with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Chemical and Drug Induced Liver Injury · United States.

Enrollment
Largest of 10
241 · median 30
Started
2024
with 1 other
Phase 1
2 of 13
none open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
Food and Drug Administration (FDA)

Among the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, this one has the largest enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 1, and was the 11th registered.

Chemical and Drug Induced Liver Injury

81 studies on the registry are indexed under Chemical and Drug Induced Liver Injury; 21 are open to participants now.

Browse Chemical and Drug Induced Liver Injury studies →

Open to participants now

2 of the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Chemical and Drug Induced Liver Injury studies recruiting now, 7 (58%) set no upper age limit and 3 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, or all of them as a file.
02

Study summary

Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. However, only limited evaluations of the risk of liver enzyme elevation of daily, lower dose CBD use are available. The potential for liver enzyme elevations with lower CBD doses with unapproved consumer products highlights a need for further research. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, leading to potential drug-drug interactions with multiple common medications. The clinical significance of many of these interactions is also unclear. Furthermore, nonclinical studies have suggested the potential for CBD to cause reproductive and endocrine effects. As such, additional high-quality clinical pharmacology studies are needed to further characterize CBD's safety profile.

The objective of this study is to characterize the effects of daily CBD use at a dose within the range of what consumers are taking as unapproved CBD products on liver enzyme elevations, drug interactions, and endocrine measures.

Read the detailed description

The cannabis plant contains bioactive compounds known as cannabinoids; delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent cannabinoids in most varieties of cannabis. The Agricultural Improvement Act (Farm Bill) of 2018 removed hemp, defined as cannabis and derivatives of cannabis with extremely low concentrations of THC, from the definition of marijuana in the Controlled Substances Act. Following this, many CBD products have been made available to consumers. However, hemp products remain subject to regulation under the Federal Food Drug \& Cosmetic Act, when applicable (e.g., as drugs, foods, dietary supplements, cosmetics, veterinary products) and the growing CBD products market raises various safety concerns, especially with long-term use.

CBD is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. However, only limited evaluations of the risk of liver enzyme elevation of daily, lower dose CBD use are available. The potential for liver enzyme elevations with CBD doses in unapproved consumer products highlights a need for further research to quantify risks at these doses. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, leading to potential drug-drug interactions with multiple common medications. The clinical significance of many of these interactions is also unclear. Furthermore, nonclinical studies have suggested the potential for CBD to cause reproductive and endocrine effects. As such, additional high-quality clinical pharmacology studies are needed to further characterize CBD's safety profile.

This study will be divided into two parts.

In Part 1, 200 healthy subjects will be randomized to 5 mg/kg/day of CBD (150 subjects) or placebo (50 subjects) for 4 weeks with weekly laboratory assessments to characterize the percentage of participants with liver enzyme elevation (primary endpoint) or meeting withdrawal criteria for potential drug-induced liver injury (secondary endpoint). Additional secondary endpoints include the change from baseline after 4 weeks of daily CBD dosing for male reproductive (testosterone and inhibin B) and thyroid hormones (thyroid stimulating hormone [TSH], triiodothyronine [T3] and thyroxine [T4]) as secondary endpoints. Exploratory endpoints include additional characterization of liver findings and other blood biomarkers.

In Part 2, 40 healthy subjects will receive either oral citalopram (20 subjects) or morphine (20 subjects) at baseline and then again after receiving CBD 5 mg/kg/day to characterize the effect of daily cannabidiol use on the plasma concentration of citalopram and morphine. Citalopram was selected because it is a common prescription medication for depression and anxiety that is metabolized by CYP2C19 and CYP3A4, which CBD inhibits. Morphine was selected because it is a common opioid analgesic that is metabolized by UGT2B7, which CBD inhibits.

03

Conditions studied

  • Cannabidiol
  • Drug Induced Liver Injury
  • Drug Interaction

Keywords

  • Cannabidiol
  • CBD
  • Liver enzyme elevation
  • Drug interactions
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject signs an institutional review board (IRB) approved written and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization) before any study related procedures are performed.
  2. Subject is a healthy, non-smoking man or woman, 18 to 55 years of age, inclusive, who weighs at least 50 kg (110 lbs) and has a of 18.5 to 33.0 kg/m2, inclusive, at Screening and check-in (Day -1).
  3. Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12-lead results, and physical examination findings at screening or, if abnormal, the abnormality is not considered (as determined and documented by the investigator or designee).
  4. Subject must have a negative test result for alcohol and illicit drugs at screening and check-in (Day -1).
  5. Participants must agree to refrain from using any of the following for the duration of the study: alcohol, nicotine containing products, marijuana or marijuana-derived products, hemp or hemp-derived products, including CBD (except for provided study drug), and illicit drugs of any kind.
  6. Subject must test negative for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) by a rapid antigen test at check-in for all study periods. If a subject's test comes back as invalid, the test can be repeated.
  7. Female subjects must be of non- (non-childbearing potential includes females defined as spontaneous amenorrhea for at least 12 months with FSH in the post-menopausal range and females who have undergone a hysterectomy) or, if they are of childbearing potential, they must: 1) have negative serum HCG at screening and check-in 2) have been strictly abstinent for 1 month before check-in (Day -1) and agree to remain strictly abstinent for the duration of the study and for at least 1 month after the last application of study drug; OR 3) be practicing 2 highly effective methods of (as determined by the investigator or designee; one of the methods must be a barrier technique) from Screening until at least 1 month after the end of the study.
  8. Male subjects must agree to practice 2 highly effective methods of birth control (as determined by the investigator or designee) beginning at check-in (Day -1) until at least 3 months after the last dose of study drug. Male subjects may not donate sperm for 90 days after the end of the study.
  9. Subject agrees to and is highly likely (as determined by the investigator) to comply with the protocol defined procedures and to complete the study.

Exclusion criteria

Exclusion Criteria:

  1. Abnormal liver labs at screening on check-in (Day -1), defined as any of the following (tests may be repeated once for confirmation at screening and check-in):

    1. Serum (ALT) or aspartate aminotransferase (AST) > 1.5 × . (The ULN for ALT will be 33 U/L for males and 25 U/L for females.)
    2. Total (TBL) > ULN.
    3. (INR) > 1.3
  2. Use or intend to use any medications/products in the 14 days prior to check-in (Day -1), unless deemed acceptable by the investigator
  3. Subject is currently participating in another clinical study of an drug or has been treated with any investigational drug within 30 days or 5 half-lives (whichever is longer) of dosing for this study.
  4. Subject has used nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, electronic cigarettes) within 6 weeks of Screening. Subjects must refrain from using these throughout the study.
  5. Subject has consumed alcohol, xanthine-containing products (e.g., tea, coffee, chocolate, cola), caffeine, kava melatonin, St Johns Wart, grapefruit, or grapefruit juice within 24 hours of check-in. Subjects must refrain from ingesting these throughout the study.
  6. Subject is unable to tolerate a controlled, quiet study conduct environment, including avoidance of music, television, movies, games, and activities that may cause excitement, emotional tension, or arousal during the prespecified time points (e.g., before and during CBD dosing).
  7. Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months before Screening, has a history of alcoholism or drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits/hard liquor)
  8. Subject has a positive test result for alcohol or drugs of misuse (amphetamines, barbiturates, benzodiazepines, cocaine, alcohol, opiates, phencyclidine, propoxyphene, and methadone) at Screening or Check-in (Day -1 [both Parts]; Day 10 [Part 2, morphine DDI]; Day 12 [Part 2, citalopram DDI]).
  9. Subject has a positive test result for cannabinoids (THC) at screening or Day -1.
  10. Subject has a history of opioid or narcotic misuse.
  11. Subject has a history of suicidal ideation or previous suicide attempts
  12. Subject has a history or evidence of a disorder, condition, or disease (e.g., cancer, [HIV], hepatic or renal impairment) that, in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  13. Subject has any signs or symptoms that are consistent with Coronavirus Disease 2019 (COVID-19) per Center for Disease Control (CDC) recommendations at screening or check-in (Day -1). These include subjects with fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea may have COVID-19. In addition, the subject has any other findings suggestive of COVID-19 risk in the opinion of the investigator.
  14. Subject has known or suspected allergies or sensitivities to the study drug or placebo components (e.g., sucralose, sesame).
  15. Subjects with a documented reaction to cannabidiol
  16. Subjects with a documented medical history of clinical disorders related to mood, anxiety or panic, including diagnosed depression, generalized anxiety disorder or panic attacks.
  17. Subject has any condition possibly affecting study drug absorption (e.g., gastrectomy, Crohn's disease, irritable bowel syndrome). Uncomplicated cholecystectomies and appendectomies may be included at the investigator's discretion.
  18. Subject has clinical laboratory test results (hematology, serum chemistry and urinalysis) at Screening or Check-In that are outside the reference ranges provided by the clinical laboratory and considered clinically significant by the investigator. Tests may be repeated once for confirmation at both Screening and Check-In.
  19. Subject has a positive test result at Screening for HIV 1 or 2 antibody, virus antibodies, or surface antigen.
  20. Subject has a mean systolic blood pressure \<85 or >145 mmHg or a mean diastolic blood pressure \<45 or >95 mmHg at either Screening or Check-in. Blood pressure will be measured in triplicate after the subject has been resting in a supine position for a minimum of 5 minutes.
  21. Subject is unable or unwilling to undergo multiple venipunctures for blood sample collection because of poor tolerability or is unlikely to complete the study due to poor venous access.
  22. Female subject is currently pregnant or lactating or was within 3 months of the study.
  23. Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days before Check-in.
  24. Subject has any other condition that precludes his or her participation in the study (as determined by the investigator).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
241 participants (actual)

Study arms

  • Active comparator
    Cannabidiol (Part 1)

    Subjects in this arm will receive oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day, for a total of 5 mg/kg cannabidiol daily for 28 days.

    Drug: Cannabidiol

  • Placebo comparator
    Placebo (Part 1)

    Subjects in this arm will receive oral solution placebo twice a day for 28 days.

    Drug: Placebo

  • Active comparator
    Cannabidiol and Citalopram Drug Interaction (Part 2)

    Subjects in this arm will receive citalopram (20 mg) on Day 1 and Day 13 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg cannabidiol daily) for 12 days (Day 6-17).

    Drug: Cannabidiol · Drug: Citalopram

  • Active comparator
    Cannabidiol and Morphine Drug Interaction (Part 2)

    Subjects in this arm will receive morphine (15 mg) on Day 1, Day 4, and Day 11 and oral solution cannabidiol at a dosage of 2.5 mg/kg twice a day (5 mg/kg CBD daily) for 9 days (Day 4-12).

    Drug: Cannabidiol · Drug: Morphine

Interventions

  • Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.

    Also known as: Epidiolex

  • DrugPlacebo

    Placebo will be administered orally twice daily for 28 days in Part 1

  • Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13.

    Also known as: Celexa

  • Morphine will be administered once at 15 mg on days 1, 4, and 11.

06

What researchers measure

Primary outcomes

  1. Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN).

    The upper limit of normal (ULN), based on consensus criteria, for the liver transaminase ALT (Alanine transaminase) is defined as 33 U/L for males and 25 U/L for females. An ALT evaluation three times the ULN for males would be 99 U/L and 75 U/L for females.

    Time frame: Days 1 through 35

  2. Part 2 - Area Under the Plasma Concentration-time Curve (AUC) of Citalopram When Administered Alone Versus When Co-administered With Cannabidiol After 7 Days of CBD Dosing.

    AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.

    Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13)

  3. Part 2 - Maximum Concentration (Cmax) of Citalopram When Administered Alone Versus When Co-administered With CBD After 7 Days of Cannabidiol Dosing.

    Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.

    Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13)

  4. Part 2 - Morphine AUC When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of CBD Dosing.

    AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

  5. Part 2 - Morphine Cmax When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of Cannabidiol Dosing.

    Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

Secondary outcomes

  1. Part 1 - Percentage of Participants Meeting Withdrawal Criteria for Potential Drug-induced Liver Injury (DILI).

    Withdrawal criteria for potential drug-induced liver-injury: laboratory results meeting any of the following criteria. * ALT or AST \> 3 x ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (\> 5%) OR * ALT elevation ≥ 5 × ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) OR * Alkaline phosphatase (ALP) elevation ≥ 2 × ULN (with accompanying elevations of gamma-glutamyl transpeptidase (GGT) in the absence of known bone pathology driving the rise in ALP level) OR * ALT elevation ≥ 3 × ULN and bilirubin concentration \> 2 × ULN

    Time frame: Days 1 through 35

  2. Part 1 - Change From Baseline in Total Testosterone in Male Participants After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for total testosterone will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Time frame: Days 1 and 29

  3. Part 1 - Change From Baseline in Inhibin B in Male Participants After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for inhibin B will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Time frame: Days 1 and 29

  4. Part 1 - Change From Baseline in Thyroid Stimulating Hormone (TSH) After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for TSH will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Time frame: Days 1 and 29

  5. Part 1 - Change From Baseline in Total T3 After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for total T3 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Time frame: Days 1 and 29

  6. Part 1 - Change From Baseline in Free T4 After Cannabidiol Administration Compared to Placebo.

    Endocrine assessments for free T4 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

    Time frame: Days 1 and 29

  7. Part 2 - Morphine-3-glucuronide (M3G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

    AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

  8. Part 2 - M3G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

    Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

  9. Part 2 - Morphine-6-glucuronide (M6G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

    AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

  10. Part 2 - M6G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

    Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)

07

Results

Posted Jul 31, 2025

Participant flow

Participant flow — Overall Study
MilestoneCannabidiol (Part 1)Placebo (Part 1)Cannabidiol and Citalopram Drug Interaction (Part 2)Cannabidiol and Morphine Drug Interaction (Part 2)
Started151502020
Completed133472018
Not completed18302

Outcome measures

PrimaryPart 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN).

The upper limit of normal (ULN), based on consensus criteria, for the liver transaminase ALT (Alanine transaminase) is defined as 33 U/L for males and 25 U/L for females. An ALT evaluation three times the ULN for males would be 99 U/L and 75 U/L for females.

Time frame:
Days 1 through 35
Reported as:
Number · percentage of participants
Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN).
percentage of participantsCannabidiol (Part 1)Placebo (Part 1)
Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper Limit of Normal (> 3 × ULN).5.6 (1.8 to 9.3)0 (0 to 7.6)
PrimaryPart 2 - Area Under the Plasma Concentration-time Curve (AUC) of Citalopram When Administered Alone Versus When Co-administered With Cannabidiol After 7 Days of CBD Dosing.

AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.

Time frame:
0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13)
Reported as:
Geometric mean · ng*hr/mL
Part 2 - Area Under the Plasma Concentration-time Curve (AUC) of Citalopram When Administered Alone Versus When Co-administered With Cannabidiol After 7 Days of CBD Dosing.
ng*hr/mLPart 2: CitalopramPart 2: Citalopram and Cannabidiol
Part 2 - Area Under the Plasma Concentration-time Curve (AUC) of Citalopram When Administered Alone Versus When Co-administered With Cannabidiol After 7 Days of CBD Dosing.1033 ± 261475 ± 24
Statistical analysis
  • Part 2: Citalopram vs Part 2: Citalopram and Cannabidiol · Mixed Models Analysis · p = <0.01 (Analyses are not adjusted for multiplicity.) · Geometric mean ratio: 1.43 · 90% CI 1.34 to 1.52Comparison was the effect of cannabidiol on citalopram compared to citalopram alone.
PrimaryPart 2 - Maximum Concentration (Cmax) of Citalopram When Administered Alone Versus When Co-administered With CBD After 7 Days of Cannabidiol Dosing.

Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis. 13 PK samples will be obtained with each citalopram dose for a total number of 26 PK samples per citalopram cohort participant. The outcome measure reported will be the geometric mean ratio for citalopram alone compared to citalopram after 7 days of CBD dosing.

Time frame:
0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after each citalopram dose (Days 1 and 13)
Reported as:
Geometric mean · ng/mL
Part 2 - Maximum Concentration (Cmax) of Citalopram When Administered Alone Versus When Co-administered With CBD After 7 Days of Cannabidiol Dosing.
ng/mLPart 2: CitalopramPart 2: Citalopram and Cannabidiol
Part 2 - Maximum Concentration (Cmax) of Citalopram When Administered Alone Versus When Co-administered With CBD After 7 Days of Cannabidiol Dosing.23 ± 2126 ± 24
Statistical analysis
  • Part 2: Citalopram vs Part 2: Citalopram and Cannabidiol · Mixed Models Analysis · p = <0.01 (Analyses are not adjusted for multiplicity.) · Geometric mean ratio: 1.12 · 90% CI 1.06 to 1.17Comparison was the effect of cannabidiol on citalopram compared to citalopram alone.
PrimaryPart 2 - Morphine AUC When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of CBD Dosing.

AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.

Time frame:
0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Reported as:
Geometric mean · ng*hr/mL
Part 2 - Morphine AUC When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of CBD Dosing.
ng*hr/mLPart 2: MorphinePart 2: Morphine and Single Dose CannabidiolPart 2: Morphine and Multiple Doses of Cannabidiol
Part 2 - Morphine AUC When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of CBD Dosing.44 ± 4547 ± 5151 ± 60
Statistical analysis
  • Part 2: Morphine vs Part 2: Morphine and Single Dose Cannabidiol · Mixed Models Analysis · p = 0.34 · Geometric mean ratio: 1.06 · 90% CI 0.96 to 1.16Comparison was the effect of a single dose of cannabidiol on morphine compared to morphine alone.
  • Part 2: Morphine vs Part 2: Morphine and Multiple Doses of Cannabidiol · Mixed Models Analysis · p = 0.10 · Geometric mean ratio: 1.12 · 90% CI 1.00 to 1.26Comparison was the effect of a multiple doses of cannabidiol on morphine compared to morphine alone.
PrimaryPart 2 - Morphine Cmax When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of Cannabidiol Dosing.

Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine alone compared to morphine after 7 days of CBD dosing.

Time frame:
0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Reported as:
Geometric mean · ng/mL
Part 2 - Morphine Cmax When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of Cannabidiol Dosing.
ng/mLPart 2: MorphinePart 2: Morphine and Single Dose CannabidiolPart 2: Morphine and Multiple Doses of Cannabidiol
Part 2 - Morphine Cmax When Administered Alone Versus When Co-administered With the First Dose of Cannabidiol and After 7 Days of Cannabidiol Dosing.8.3 ± 409.9 ± 459.3 ± 31
Statistical analysis
  • Part 2: Morphine vs Part 2: Morphine and Single Dose Cannabidiol · Mixed Models Analysis · p = 0.02 · Geometric mean ratio: 1.19 · 90% CI 1.05 to 1.35Comparison was the effect of a single dose of cannabidiol on morphine compared to morphine alone.
  • Part 2: Morphine vs Part 2: Morphine and Multiple Doses of Cannabidiol · Mixed Models Analysis · p = 0.29 · Geometric mean ratio: 1.11 · 90% CI 0.94 to 1.30Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone.
SecondaryPart 1 - Percentage of Participants Meeting Withdrawal Criteria for Potential Drug-induced Liver Injury (DILI).

Withdrawal criteria for potential drug-induced liver-injury: laboratory results meeting any of the following criteria. * ALT or AST \> 3 x ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (\> 5%) OR * ALT elevation ≥ 5 × ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) OR * Alkaline phosphatase (ALP) elevation ≥ 2 × ULN (with accompanying elevations of gamma-glutamyl transpeptidase (GGT) in the absence of known bone pathology driving the rise in ALP level) OR * ALT elevation ≥ 3 × ULN and bilirubin concentration \> 2 × ULN

Time frame:
Days 1 through 35
Reported as:
Number · percentage of participants
Part 1 - Percentage of Participants Meeting Withdrawal Criteria for Potential Drug-induced Liver Injury (DILI).
percentage of participantsCannabidiol (Part 1)Placebo (Part 1)
Part 1 - Percentage of Participants Meeting Withdrawal Criteria for Potential Drug-induced Liver Injury (DILI).4.9 (1.3 to 8.4)0 (0 to 7.6)
SecondaryPart 1 - Change From Baseline in Total Testosterone in Male Participants After Cannabidiol Administration Compared to Placebo.

Endocrine assessments for total testosterone will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

Time frame:
Days 1 and 29
Reported as:
Least squares mean · ng/dL
Part 1 - Change From Baseline in Total Testosterone in Male Participants After Cannabidiol Administration Compared to Placebo.
ng/dLCannabidiol (Part 1)Placebo (Part 1)
Part 1 - Change From Baseline in Total Testosterone in Male Participants After Cannabidiol Administration Compared to Placebo.5.0 (-20.0 to 30.0)-13.6 (-57.1 to 29.9)
SecondaryPart 1 - Change From Baseline in Inhibin B in Male Participants After Cannabidiol Administration Compared to Placebo.

Endocrine assessments for inhibin B will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

Time frame:
Days 1 and 29
Reported as:
Least squares mean · pg/mL
Part 1 - Change From Baseline in Inhibin B in Male Participants After Cannabidiol Administration Compared to Placebo.
pg/mLCannabidiol (Part 1)Placebo (Part 1)
Part 1 - Change From Baseline in Inhibin B in Male Participants After Cannabidiol Administration Compared to Placebo.5.8 (0.8 to 10.7)8.2 (-0.0 to 16.5)
SecondaryPart 1 - Change From Baseline in Thyroid Stimulating Hormone (TSH) After Cannabidiol Administration Compared to Placebo.

Endocrine assessments for TSH will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

Time frame:
Days 1 and 29
Reported as:
Least squares mean · mU/mL
Part 1 - Change From Baseline in Thyroid Stimulating Hormone (TSH) After Cannabidiol Administration Compared to Placebo.
mU/mLCannabidiol (Part 1)Placebo (Part 1)
Part 1 - Change From Baseline in Thyroid Stimulating Hormone (TSH) After Cannabidiol Administration Compared to Placebo.0.073 (-0.003 to 0.148)0.005 (-0.124 to 0.134)
SecondaryPart 1 - Change From Baseline in Total T3 After Cannabidiol Administration Compared to Placebo.

Endocrine assessments for total T3 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

Time frame:
Days 1 and 29
Reported as:
Least squares mean · ng/mL
Part 1 - Change From Baseline in Total T3 After Cannabidiol Administration Compared to Placebo.
ng/mLCannabidiol (Part 1)Placebo (Part 1)
Part 1 - Change From Baseline in Total T3 After Cannabidiol Administration Compared to Placebo.-0.006 (-0.023 to 0.011)0.014 (-0.015 to 0.043)
SecondaryPart 1 - Change From Baseline in Free T4 After Cannabidiol Administration Compared to Placebo.

Endocrine assessments for free T4 will be obtained through blood samples. A linear mixed effect model will be utilized to obtain least squares means for each treatment group.

Time frame:
Days 1 and 29
Reported as:
Least squares mean · ng/mL
Part 1 - Change From Baseline in Free T4 After Cannabidiol Administration Compared to Placebo.
ng/mLCannabidiol (Part 1)Placebo (Part 1)
Part 1 - Change From Baseline in Free T4 After Cannabidiol Administration Compared to Placebo.-0.014 (-0.025 to -0.003)-0.012 (-0.031 to 0.006)
SecondaryPart 2 - Morphine-3-glucuronide (M3G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.

Time frame:
0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Reported as:
Geometric mean · ng*hr/mL
Part 2 - Morphine-3-glucuronide (M3G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.
ng*hr/mLPart 2: MorphinePart 2: Morphine and Single Dose CannabidiolPart 2: Morphine and Multiple Doses of Cannabidiol
Part 2 - Morphine-3-glucuronide (M3G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.2416 ± 182450 ± 172382 ± 14
Statistical analysis
  • Part 2: Morphine vs Part 2: Morphine and Single Dose Cannabidiol · Mixed Models Analysis · p = 0.47 · Geometric mean ratio: 1.01 · 90% CI 0.98 to 1.05Comparison was the effect of a single dose of cannabidiol on morphine compared to morphine alone.
  • Part 2: Morphine vs Part 2: Morphine and Multiple Doses of Cannabidiol · Mixed Models Analysis · p = 0.73 · Geometric mean ratio: 0.99 · 90% CI 0.96 to 1.03Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone.
SecondaryPart 2 - M3G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-3-glucuronide (M3G) alone compared to morphine-3-glucuronide (M3G) after 7 days of CBD dosing.

Time frame:
0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Reported as:
Geometric mean · ng/mL
Part 2 - M3G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.
ng/mLPart 2: MorphinePart 2: Morphine and Single Dose CannabidiolPart 2: Morphine and Multiple Doses of Cannabidiol
Part 2 - M3G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.265 ± 21296 ± 29256 ± 25
Statistical analysis
  • Part 2: Morphine vs Part 2: Morphine and Single Dose Cannabidiol · Mixed Models Analysis · p = 0.03 · Geometric mean ratio: 1.12 · 90% CI 1.03 to 1.21Comparison was the effect of a single dose of cannabidiol on morphine compared to morphine alone.
  • Part 2: Morphine vs Part 2: Morphine and Multiple Doses of Cannabidiol · Mixed Models Analysis · p = 0.66 · Geometric mean ratio: 0.98 · 90% CI 0.91 to 1.06Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone.
SecondaryPart 2 - Morphine-6-glucuronide (M6G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

AUC will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.

Time frame:
0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Reported as:
Geometric mean · ng*hr/mL
Part 2 - Morphine-6-glucuronide (M6G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.
ng*hr/mLPart 2: MorphinePart 2: Morphine and Single Dose CannabidiolPart 2: Morphine and Multiple Doses of Cannabidiol
Part 2 - Morphine-6-glucuronide (M6G) AUC When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.327 ± 30355 ± 28416 ± 27
Statistical analysis
  • Part 2: Morphine vs Part 2: Morphine and Single Dose Cannabidiol · Mixed Models Analysis · p = 0.13 · Geometric mean ratio: 1.08 · 90% CI 0.99 to 1.18Comparison was the effect of a single dose of cannabidiol on morphine compared to morphine alone.
  • Part 2: Morphine vs Part 2: Morphine and Multiple Doses of Cannabidiol · Mixed Models Analysis · p = <0.01 · Geometric mean ratio: 1.26 · 90% CI 1.17 to 1.36Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone.
SecondaryPart 2 - M6G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.

Cmax will be determined by collecting pharmacokinetic (PK) blood samples and calculated using noncompartmental analysis.13 PK samples will be obtained with each morphine dose for a total number of 39 PK samples per morphine cohort participant. The outcome measure reported will be the geometric mean ratio for morphine-6-glucuronide (M6G) alone compared to morphine-6-glucuronide (M6G) after 7 days of CBD dosing.

Time frame:
0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours after each morphine dose (Days 1, 4, and 11)
Reported as:
Geometric mean · ng/mL
Part 2 - M6G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.
ng/mLPart 2: MorphinePart 2: Morphine and Single Dose CannabidiolPart 2: Morphine and Multiple Doses of Cannabidiol
Part 2 - M6G Cmax When Morphine is Administered Alone Versus When Co-administered With Cannabidiol.47 ± 2451 ± 2852 ± 28
Statistical analysis
  • Part 2: Morphine vs Part 2: Morphine and Single Dose Cannabidiol · Mixed Models Analysis · p = 0.12 · Geometric mean ratio: 1.08 · 90% CI 1.00 to 1.17Comparison was the effect of a single dose of cannabidiol on morphine compared to morphine alone.
  • Part 2: Morphine vs Part 2: Morphine and Multiple Doses of Cannabidiol · Mixed Models Analysis · p = 0.07 · Geometric mean ratio: 1.11 · 90% CI 1.01 to 1.21Comparison was the effect of multiple doses of cannabidiol on morphine compared to morphine alone.

Adverse events

Collected over Part 1: 36 days Part 2: 24 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cannabidiol (Part 1)0/151 (0%)0/151 (0%)43/151 (28.5%)
Placebo (Part 1)0/50 (0%)0/50 (0%)9/50 (18%)
Cannabidiol and Citalopram Drug Interaction (Part 2)0/20 (0%)0/20 (0%)7/20 (35%)
Cannabidiol and Morphine Drug Interaction (Part 2)0/20 (0%)0/20 (0%)5/20 (25%)
Most frequent other events
Showing 10 of 48
Most frequent other events
EventCannabidiol (Part 1)Placebo (Part 1)Cannabidiol and Citalopram Drug Interaction (Part 2)Cannabidiol and Morphine Drug Interaction (Part 2)
NauseaGastrointestinal disorders0/1510/503/201/20
DiarrheaGastrointestinal disorders6/1510/502/201/20
HeadacheGeneral disorders4/1510/502/200/20
Hepatic Enzyme IncreaseHepatobiliary disorders8/1510/500/200/20
Back PainGeneral disorders0/1511/500/201/20
DizzinessNervous system disorders4/1510/500/201/20
FlatulenceGastrointestinal disorders1/1510/501/200/20
Upper Respiratory Tract InfectionInfections and infestations4/1512/500/201/20
Abdominal discomfortGastrointestinal disorders0/1510/501/200/20
AbrasionSkin and subcutaneous tissue disorders0/1510/501/200/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cannabidiol (Part 1)Placebo (Part 1)Citalopram and Cannabidiol (Part 2)Morphine and Cannabidiol (Part 2)Total
Median36 (31 to 44)32 (29 to 41)37 (29 to 49)38 (35 to 44)36 (30.5 to 43)
Sex: Female, Male
Sex: Female, Male(Participants)Cannabidiol (Part 1)Placebo (Part 1)Citalopram and Cannabidiol (Part 2)Morphine and Cannabidiol (Part 2)Total
Female682178104
Male83291312137
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cannabidiol (Part 1)Placebo (Part 1)Citalopram and Cannabidiol (Part 2)Morphine and Cannabidiol (Part 2)Total
American Indian or Alaska Native10001
Asian33017
Native Hawaiian or Other Pacific Islander00000
Black or African American642398104
White7722810117
More than one race21115
Unknown or Not Reported41207
Median Body Weight
Median Body Weight(kg)Cannabidiol (Part 1)Placebo (Part 1)Citalopram and Cannabidiol (Part 2)Morphine and Cannabidiol (Part 2)Total
Median80.2 (50.6 to 110.0)75.9 (53.0 to 103.0)79.5 (59.6 to 102.1)82.7 (58.9 to 102)80.1 (50.6 to 110.0)
Median Height
Median Height(m)Cannabidiol (Part 1)Placebo (Part 1)Citalopram and Cannabidiol (Part 2)Morphine and Cannabidiol (Part 2)Total
Median1.71 (1.53 to 1.94)1.72 (1.52 to 1.87)1.74 (1.54 to 1.87)1.76 (1.53 to 1.90)1.72 (1.52 to 1.94)
Median Body Mass Index
Median Body Mass Index(kg/m2)Cannabidiol (Part 1)Placebo (Part 1)Citalopram and Cannabidiol (Part 2)Morphine and Cannabidiol (Part 2)Total
Median27.1 (18.6 to 33)26 (19.2 to 32)26.6 (21.7 to 32.1)26.7 (22.1 to 32.3)26.7 (18.6 to 33)
08

Study locations

1 site
  • Spaulding Clinical Research
    West Bend, Wisconsin 53095, United States
09

References and documents

Publications

  • 1. U.S. Food and Drug Administration (FDA) Science Board. (2022, June 3). Background materials for the June 14, 2022 meeting of the Science Board to the FDA. Retrieved from https://www.fda.gov/advisory-committees/advisory-committee-roster/science-board-fda/2022-meetings#event-materials.
  • 2. Cannabidiol (Epidiolex ®) oral solution label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
  • Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023 Jun;293(6):724-752. doi: 10.1111/joim.13627. Epub 2023 Mar 13. PubMed 36912195 ↗
  • Crippa JAS, Zuardi AW, Guimaraes FS, Campos AC, de Lima Osorio F, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Pacheco JC, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Pereira-Lima K, Sen S, Andraus MH, Hallak JEC; Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open. 2021 Aug 2;4(8):e2120603. doi: 10.1001/jamanetworkopen.2021.20603. PubMed 34387679 ↗
  • 5. U.S. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf
  • 6. EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), Turck, D, Bohn, T, Castenmiller, J, De Henauw, S, Hirsch-Ernst, KI, Maciuk, A, Mangelsdorf, I, McArdle, HJ, Naska, A, Pelaez, C, Pentieva, K, Siani, A, Thies, F, Tsabouri, S, Vinceti, M, Cubadda, F, Frenzel, T, Heinonen, M, Marchelli, R, Neuhäuser-Berthold, M, Poulsen, M, Prieto Maradona, M, Schlatter, JR, Trezza, V, van Loveren, H, Albert, O, Dumas, C, Germini, A, Gelbmann, W, Kass, G, Kouloura, E, Noriega Fernandez, E, Rossi, A and Knutsen, HK, 2022. Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. EFSA Journal 2022; 20(6):7322, 25 pp. https://doi.org/10.2903/j.efsa.2022.7322
  • Carvalho RK, Andersen ML, Mazaro-Costa R. The effects of cannabidiol on male reproductive system: A literature review. J Appl Toxicol. 2020 Jan;40(1):132-150. doi: 10.1002/jat.3831. Epub 2019 Jul 17. PubMed 31313338 ↗
  • Tallon MJ, Child R. Subchronic oral toxicity assessment of a cannabis extract. Regul Toxicol Pharmacol. 2023 Oct;144:105496. doi: 10.1016/j.yrtph.2023.105496. Epub 2023 Sep 19. PubMed 37734651 ↗
  • Anderson LL, Doohan PT, Oldfield L, Kevin RC, Arnold JC, Berger M, Amminger GP, McGregor IS. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. J Clin Psychopharmacol. 2021 Sep-Oct 01;41(5):525-533. doi: 10.1097/JCP.0000000000001427. PubMed 34121064 ↗
  • Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics. 2003 Mar-Apr;44(2):167-71. doi: 10.1176/appi.psy.44.2.167. PubMed 12618536 ↗
  • 11. Citalopram (Celexa ®) tablet label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf
  • 12. Morphine Sulfate tablet label obtained from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022207s010lbl.pdf
  • Iannone LF, Arena G, Battaglia D, Bisulli F, Bonanni P, Boni A, Canevini MP, Cantalupo G, Cesaroni E, Contin M, Coppola A, Cordelli DM, Cricchiuti G, De Giorgis V, De Leva MF, De Rinaldis M, d'Orsi G, Elia M, Galimberti CA, Morano A, Granata T, Guerrini R, Lodi MAM, La Neve A, Marchese F, Masnada S, Michelucci R, Nosadini M, Pilolli N, Pruna D, Ragona F, Rosati A, Santucci M, Spalice A, Pietrafusa N, Striano P, Tartara E, Tassi L, Papa A, Zucca C, Russo E, Mecarelli O; CBD LICE Italy Study Group. Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. Front Neurol. 2021 May 20;12:673135. doi: 10.3389/fneur.2021.673135. eCollection 2021. PubMed 34093420 ↗
  • 14. Sharbaf Shoar N, Fariba KA, Padhy RK. Citalopram. StatPearls https://www.ncbi.nlm.nih.gov/books/NBK482222/
  • Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806-15. doi: 10.1038/clpt.2011.58. Epub 2011 May 4. PubMed 21544079 ↗
  • Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clin Transl Sci. 2023 Jan;16(1):10-30. doi: 10.1111/cts.13425. Epub 2022 Oct 19. PubMed 36259271 ↗
  • Florian J, Salcedo P, Burkhart K, Shah A, Chekka LMS, Keshishi D, Patel V, Yang S, Fein M, DePalma R, Matta M, Strauss DG, Rouse R. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 1;185(9):1070-1078. doi: 10.1001/jamainternmed.2025.2366. PubMed 40622698 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Plan is to make data from the study publicly available as part of a manuscript publication. In addition, the protocol and statistical analysis plan will be made available online at this site as well as with any eventual publications.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will become available at the time of manuscript publication.

Access criteria: No restrictions.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Sep 2024, 6 months.

Results were first posted in Jul 2025, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Jan 5, 2024
StartActual
Feb 8, 2024
Primary completionActual
Sep 6, 2024
CompletionActual
Sep 6, 2024
Results first posted
Jul 31, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06192589
Lead sponsor
Food and Drug Administration (FDA)
Collaborators
Spaulding Clinical Research LLC
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Feb 8, 2024
Primary completion
Sep 6, 2024
Completion
Sep 6, 2024
Results posted
Jul 31, 2025
Last update
Jul 31, 2025

Study contacts

Melanie Fein, MD
principal investigator · Spaulding Clinical Research LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cannabidiol · Citalopram · Morphine

Start the discussion